{"cdcTestId":"2022-0020","testcaseName":"Patient is 50 years and has been administered Dose #1  as Janssen and Dose #2 as Pfizer and Dose #3 as Moderna","vaccineGroup":"COVID-19","evaluationTestType":"All Valid: Forecast Test","forecastTestType":"Recommended based on interval","assessmentDate":"2022-09-03T00:00:00","patient":{"dob":"1972-01-18T00:00:00","gender":"M"},"evaluation":{"seriesStatus":"Not complete","administeredDoses":[{"dateAdministered":"2021-08-18T00:00:00","vaccineName":"Janssen (J\u0026J) COVID-19 Vaccine","cvx":"212","mvx":"JSN","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2021-09-15T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-08-15T00:00:00","vaccineName":"Moderna COVID-19 Vaccine (non-US Spikevax)","cvx":"207","mvx":"MOD","evaluationStatus":"Valid","evaluationReason":null}]},"forecast":{"forecastNum":"4","earliestDate":"2022-10-10T00:00:00","recommendedDate":"2022-10-10T00:00:00","pastDueDate":"0001-01-01T00:00:00"},"doses":[{"dateAdministered":"2021-08-18T00:00:00","vaccineName":"Janssen (J\u0026J) COVID-19 Vaccine","cvx":"212","mvx":"JSN","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2021-09-15T00:00:00","vaccineName":"Pfizer-BioNTech COVID-19 Vaccine (EUA labeled)  COMIRNATY (BLA labeled)","cvx":"208","mvx":"PFR","evaluationStatus":"Valid","evaluationReason":null},{"dateAdministered":"2022-08-15T00:00:00","vaccineName":"Moderna COVID-19 Vaccine (non-US Spikevax)","cvx":"207","mvx":"MOD","evaluationStatus":"Valid","evaluationReason":null}],"dateAdded":"2020-10-06T20:00:00","dateUpdated":"2022-09-27T11:02:52.696","generalDescription":"This test case describes when a patient that is 50 years or older and has been administered a Janssen Covid-19 as a first dose and a Pfizer Covid-19 vaccine as a second (first booster) and Moderna and a third (second booster) dose that another dose (bivalent) should be forecast.","changedInVersion":"4.27","reasonForChange":"v4.27 Updated test case to align with the current Interim Clinical Considerations (09/2/2022) for a new bivalent mRNA booster after completion of a monovalent primary series; it replaces all prior booster recommendations for this age group."}